Other substances

Lopinavir

Retroviral protease inhibitor.

Phase of research

Recommended by China's NHC Guidelines

How it helps

Antiviral

Drug status

Used to treat other disease

27
 Supporting references
0
 Contradictory references
344
 AI-suggested references
39
 Clinical trials

General information

Lopinavir is a peptidomimetic retroviral protease inhibitor. It is used in combination with ritonavir for the treatment of HIV (NCIt).

Lopinavir/ritonavir therapy used to be one of the antiviral therapies of COVID-19 recommended by China's National Health Commission guidelines. It is NO longer recomended, however (Gui-Qiang et al., 2021).

On July 4, 2020, WHO announced that the lopinavir/ritonavir treatment arm of the Solidarity trial in hospitalized patients with COVID-19 was discontinued.

RECOVERY trial chief investigators stated that based on NO clinical benefit to hospitalized COVID-19 patients treated with lopinavir/ritonavir, further patient recruitment was halted.

A living WHO guideline on drugs for covid-19 (as of March 4, 2022) strongly recommends AGAINST the use of lopinavir/ritonavir combination for the treatment of COVID-19.

Lopinavir on DrugBank
Lopinavir on PubChem
Lopinavir on Wikipedia

Marketed as

ALUVIRAN; KALETRA (fixed-dose with Ritonavir); LOPINAVIR AND RITONAVIR (fixed-dose with Ritonavir)

 

Structure image - Lopinavir

CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O

Supporting references

Link Tested on Impact factor Notes Publication date
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.
Patients

Combination of lopinavir/ritonavir (Kaletra®), arbidol, and Shufeng Jiedu Capsule (SFJDC, a traditional Chinese medicine)

 Mar/16/2020
[Potential antiviral therapeutics for 2019 Novel Coronavirus].
Similar viruses

In combination with ritonavir or ritonavir and interferon-beta

 Feb/05/2020
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.
Patients

14.9 % of patients received lopinavir/ritonavir therapy

 Mar/13/2020
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.
Patients

Lopinavir-ritonavir combination was used to treat 5 patients also requiring supplemental oxygen. For 3 of the 5 patients, fever resolved and supplemental oxygen requirement was reduced within 3 days, whereas 2 deteriorated with progressive respiratory failure. Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results.

 Mar/03/2020
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Patients

Used as lopinavir/ritonavir (Days 1–14: 400 mg/100 mg twice daily) plus IFN-α by aerosol inhalation (5 million U twice daily). Less effective than favipiravir plus IFN-α.

 Mar/18/2020
Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases
in silico Feb/18/2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
in silico

Oral, in combination with ritonavir: lopinavir/ritonavir 200 mg/50 mg/capsule, 2 capsules each time, 2 times/day


Oral, in combination with ritonavir: lopinavir/ritonavir 200 mg/50 mg/capsule, 2 capsules each time, 2 times/day

 Feb/22/2020
A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19
Preprint 		Patients

Better in combination with Novaferon and Ritonavir than only with Ritonavir

 Apr/29/2020
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
Small molecule Randomized controlled open trial 		Patients 3.62

lopinavir/ritonavir (400mg/100mg, bid, po.) in combination with interferon alpha inhalation (100,000 iu, tid or qid)

 Oct/25/2020
IDentif.AI: Artificial Intelligence Pinpoints Remdesivir in Combination with Ritonavir and Lopinavir as an Optimal Regimen Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
in silico

optimal combination therapy against SARS-CoV-2 was comprised of remdesivir, ritonavir, and lopinavir

 May/08/2020
Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro
Preprint 		VERO E6 cell cultures Apr/08/2020
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Patients

Combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days is better than lopinavir-ritonavir in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19

 May/08/2020
Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms
in silico Apr/15/2020
Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro
Preprint In silico 		VERO E6 cell cultures

synergistic effect in combination with triflupromazine hydrochloride, amodiaquine or arbidol

 Jul/01/2020
A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients
Patients 3.48

In a fixed-dose combination with Ritonavir. Retrospective study of patients who were aged 18-65 years, were classified as non-severe cases on admission, received treatment at least 72 hours, were admitted into hospital after less than seven days from symptom onset. Sample size 51 patients (+59 control). Dosage 500 mg (LPV/r) twice daily. Endpoints - symptom development/duration; chest CT improvement time; negative conversion of viral nucleic acid.

 Jul/22/2020
Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server
in silico 4.55

Predicted to bind a SARS-CoV-2 protein structural feature.

 Aug/11/2020
Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR.
Case report 		Patients 1.72

Combination of lopinavir/ritonavir (Kaletra, AbbVie)

 Feb/17/2020
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate
Preprint 		Calu-3 human airway epithelial cells

higher IC50 value in Calu-3 cells than VERO E6 cells

 May/12/2020
In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins
Spike protein 3CLpro In silico 		in silico 4.07

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Sep/07/2020
MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs
3CLpro Small molecule In silico 		in silico 8.99

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Oct/20/2020
Reprofiling of approved drugs against SARS-CoV-2 main protease: an in-silico study
3CLpro Polysaccharide Small molecule In silico 		in silico 3.22

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Nov/12/2020
Effectiveness of lopinavir/ritonavir on covid-19 related pneumonia in a child with Covid-19 associated Kawasaki disease
Small molecule Case report 		Kawasaki disease child patient 0.84

In a fixed-dose with ritonavir. Overall clinical improvement in a 10-year-old patient with COVID-19-associated Kawasaki disease after lopinavir/ritonavir treatment (preceded by unsuccessful hydroxychloroquine and oseltamivir treatment). Dosage: 300 mg daily for 14 days.

 Nov/13/2020
SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study
ACE2 TMPRSS2 Small molecule In silico 		in silico 3.26

Predicted to target both TMPRSS2 and ACE2.

 Feb/02/2021
Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
3CLpro Small molecule In silico 		in silico 1.77

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Dec/11/2020
IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐Cov‐2) with digital drug development
AI Small molecule In vitro In silico 		in silico (AI); AC16 and THLE-2 cells (cytotoxicity); Vero E6 cells 6.09

Based on computational assessment and in vitro validation,

 Nov/10/2020
A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine...
Small molecule Randomized controlled double-blind trial Moderate severity Mild severity 		Mild to moderate COVID-19 patients 2.44

In combination with

 Feb/09/2021

AI-suggested references

Link Publication date
[Clinical efficacy and safety of different antiviral regimens in patients with coronavirus disease 2019].
Jul/20/2021
Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs.
Feb/15/2021
Structure-based virtual screening, molecular dynamics and binding affinity calculations of some potential phytocompounds against SARS-CoV-2.
Oct/13/2021
Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.
Jan/28/2021
The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment
Oct/24/2021
Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone.
Sep/30/2021
Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach.
Apr/06/2022
[Clinical study of artesunate in the treatment of coronavirus disease 2019].
Jun/13/2020
[Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "BromhexIne and Spironolactone for CoronavirUs Infection requiring hospiTalization (BISCUIT)"].
Jul/30/2020
Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome.
Feb/23/2022
In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon beta-1a differed from standard care for in-hospital mortality.
Oct/19/2021
In silico screening of therapeutic potentials from Strychnos nux-vomica against the dimeric main protease (Mpro) structure of SARS-CoV-2.
Mar/24/2021
Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.
Nov/07/2020
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.
Jun/04/2020
Rutaretin1'-(6''-sinapoylglucoside): promising inhibitor of COVID 19 mpro catalytic dyad from the leaves of Pittosporum dasycaulon miq (Pittosporaceae).
Jan/27/2022
Identification of Main Protease of Coronavirus SARS-CoV-2 (Mpro) Inhibitors from Melissa officinalis.
Mar/01/2021
Synthetic Attempts Towards Eminent Anti-Viral Candidates of SARS-CoV.
Jan/07/2022
[The efficacy and safety of lopinavir/ritonavir and arbidol in patients with coronavirus disease 2019].
Apr/27/2020
Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19.
Jun/23/2020
Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study.
Nov/26/2020
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Dec/16/2021
Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19.
Apr/03/2022
Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Feb/20/2021
Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.
Jan/04/2021
Thiazole-based SARS-CoV-2 protease (COV Mpro ) inhibitors: Design, synthesis, enzyme inhibition, and molecular modeling simulations.
Jan/20/2021
SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.
Jun/27/2020
Evaluation of phytoconstituents of Tinospora cordifolia against K417N and N501Y mutant spike glycoprotein and main protease of SARS-CoV-2- an in silico study.
Apr/25/2022
Pomegranate peel polyphenols prophylaxis against SARS-CoV-2 main protease by in-silico docking and molecular dynamics study.
Sep/27/2021
Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?
Nov/30/2021
Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
Jan/29/2021
Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery.
May/12/2022
Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.
May/06/2020
Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 through a Molecular Docking Study.
Mar/01/2022
Long-term application of hydroxychloroquine could not prevent the infection of COVID-19.
Mar/02/2021
The Antiviral and Antimalarial Drug Repurposing in Quest of Chemotherapeutics to Combat COVID-19 Utilizing Structure-Based Molecular Docking.
Aug/26/2020
Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2.
Aug/08/2020
In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.
Jan/05/2021
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.
Apr/21/2020
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Jul/02/2021
Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Mar/10/2022
Inhibition effects of eight anti-coronavirus drugs on glycosides metabolism and glycosidases in human gut microflora.
Sep/20/2021
Silybin B and Cianidanol Inhibit Mpro and Spike Protein of SARS-CoV-2: Evidence from in silico Molecular Docking Studies.
Dec/12/2020
Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19).
Aug/07/2020
Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies.
Aug/27/2021
Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Nov/02/2021
The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review.
Dec/03/2021
Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
Feb/25/2021
Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis.
Jan/29/2021
In Vitro Data of Current Therapies for SARS-CoV-2.
Jun/24/2020
Here we go again? A new pandemic of the 21st century.
Jul/16/2020
Phenylbenzopyrone of Flavonoids as a Potential Scaffold to Prevent SARSCoV-2 Replication by Inhibiting its MPRO Main Protease.
Jan/29/2021
Antiviral potential of some novel structural analogs of standard drugs repurposed for the treatment of COVID-19.
Apr/22/2022
The dual role of anti-viral therapy in the treatment of Coronavirus disease 2019.
Jan/06/2022
Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
Mar/03/2020
Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case report.
May/15/2020
Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial.
Oct/08/2020
Potential of Marine Terpenoids against SARS-CoV-2: An In Silico Drug Development Approach.
Oct/20/2021
Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19
Sep/29/2021
In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2
Apr/01/2022
Survival of the hospitalized patients with COVID-19 receiving atorvastatin: A randomized clinical trial
Mar/22/2022
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
May/03/2020
Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.
Aug/13/2020
Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies
Jul/28/2020
A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2.
Nov/30/2020
Aurintricarboxylic acid and its metal ion complexes in comparative virtual screening versus Lopinavir and Hydroxychloroquine in fighting COVID-19 pandemic: Synthesis and characterization.
Jan/28/2021
Low-dose radiation therapy in the management of COVID-19 pneumonia (LOWRAD-Cov19). Final results of a prospective phase I-II trial
Mar/31/2022
Targeting Lipid Rafts as a Strategy Against Coronavirus
Jul/30/2021
Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab
Jun/02/2020
Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice
Aug/29/2020
Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment.
Jul/04/2020
SAFETY PROFILE OF TREATMENTS ADMINISTERED IN COVID 19 INFECTION IN PREGNANT WOMEN
Jan/10/2022
No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coron
Jul/14/2020
Phytochemicals present in Indian ginseng possess potential to inhibit SARS-CoV-2 virulence: A molecular docking and MD simulation study.
May/24/2021
The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
Nov/18/2021
Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors
Nov/05/2021
Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form
Nov/21/2020
A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2
Jan/17/2022
Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients
Jun/05/2021
Influence of traditional Chinese medicines on the in vivo metabolism of lopinavir/ritonavir based on UHPLC-MS/MS analysis.
Jun/25/2021
Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19
Nov/30/2020
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients
Jul/28/2021
Depicting the inhibitory potential of polyphenols from Isatis indigotica root against the main protease of SARS CoV-2 using computational approaches
Dec/09/2020
Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial
Feb/24/2021
In-silico network-based analysis of drugs used against COVID-19: Human well-being study.
Jan/21/2021
Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD
Feb/18/2021
Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial.
Apr/13/2021
Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use
May/05/2020
A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Mo
Aug/28/2021
The inhibitory effect of some natural bioactive compounds against SARS-CoV-2 main protease: insights from molecular docking analysis and molecular dynamic simulation
Aug/02/2020
Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.
Oct/13/2020
Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations
Aug/24/2021
Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies
Jul/30/2021
Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study
Aug/11/2021
Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial
Mar/24/2022
Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019.
Jun/22/2020
Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial
Nov/10/2021
Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection
Nov/23/2020
Remdesivir Strongly Binds to RNA-Dependent RNA Polymerase, Membrane Protein, and Main Protease of SARS-CoV-2: Indication From Molecular Modeling and Simulations.
Jul/07/2021
No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison.
Apr/22/2021
Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study.
Jul/11/2021
On a knife's edge of a COVID-19 pandemic: is containment still possible?
Mar/09/2020
Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus
Dec/01/2021
An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study
May/13/2020
Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China
May/06/2020
Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study
May/14/2020
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19
Feb/01/2022
SARS-CoV-2: From the pathogenesis to potential anti-viral treatments
Feb/02/2021
Potential benefits of combination of Nigella sativa and Zn supplements to treat COVID-19.
Jun/24/2020
Repurposing drugs and identification of inhibitors of integral proteins (spike protein and main protease) of SARS-CoV-2
Apr/15/2020
Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019
Apr/10/2020
Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.
Jun/10/2021
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Aug/24/2020
Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study
Apr/23/2020
Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients.
Jul/30/2020
Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19 - An in silico study.
Jan/04/2021
Antibody Responses and the Effects of Clinical Drugs in COVID-19 Patients
Jul/26/2021
GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection
Sep/11/2020
The Use of Antiviral Agents against SARS-CoV-2: Ineffective or Time and Age Dependent Result? A Retrospective, Observational Study among COVID-19 Older Adults
Feb/10/2021
Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial.
Aug/24/2020
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
Apr/03/2020
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
Sep/14/2021
Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CLpro): an in silico screening of alkaloids and terpenoids from African medicinal plants
Dec/07/2021
De novo design, retrosynthetic analysis and combinatorial synthesis of a hybrid antiviral (VTAR-01) to inhibit the interaction of SARS-CoV2 spike glycoprotein with human angiotensin-converting enzyme 2
Jan/05/2021
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
Jul/18/2020
Protease Inhibitor Use in COVID-19.
Aug/14/2020
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
Aug/09/2021
Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients
Jul/29/2021
Comparative therapeutic efficacy of interferon alpha-2b and combination lopinavir/ritonavir plus interferon alpha-2b against SARS-CoV-2.
Aug/30/2021
Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation
Mar/05/2021
Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
Sep/07/2020
Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro
Dec/02/2021
Design and synthesis of novel phe-phe hydroxyethylene derivatives as potential coronavirus main protease inhibitors
Oct/18/2020
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus
Apr/21/2020
Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation
Aug/03/2021
Favipiravir-based regimen for coronavirus disease 2019 pneumonia for a 47-day-old male newborn.
Oct/15/2020
Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019
Jun/18/2020
In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.
Aug/03/2020
Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Sep/04/2021
Screening of natural compounds from Cyperus rotundus Linn against SARS-CoV-2 main protease (Mpro): An integrated computational approach.
May/29/2021
Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.
Oct/14/2020
Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation.
Aug/07/2021
Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic
Dec/04/2020
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19
Mar/04/2021
Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study
Jul/30/2021
Arjunetin as a promising drug candidate against SARS-CoV-2: molecular dynamics simulation studies
Sep/17/2021
High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19
Jul/01/2021
Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study
Aug/30/2021
Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients.
Oct/23/2020
Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics
Sep/08/2021
Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China
Feb/01/2022
Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach.
Sep/24/2020
Anticipated pharmacological role of Aviptadil on COVID-19
Nov/30/2021
Flavonoids from Siparuna cristata as Potential Inhibitors of SARS-CoV-2 Replication.
Jul/20/2021
Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings
May/13/2021
Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome
Sep/24/2020
An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia
Sep/30/2021
Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019
Aug/24/2020
Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan.
Apr/30/2020
Molecular basis of quercetin as a plausible common denominator of macrophage-cholesterol-fenofibrate dependent potential COVID-19 treatment axis.
Jun/12/2021
Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector.
Oct/25/2020
beta-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization
Apr/07/2022
Potential specific therapies in COVID-19
May/22/2020
Efficacy of lopinavir-ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis
Jan/31/2022
A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19
Sep/17/2020
In Silico Mining of Terpenes from Red-Sea Invertebrates for SARS-CoV-2 Main Protease (Mpro) Inhibitors.
Apr/05/2021
Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study
Jun/23/2021
Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection.
May/11/2021
Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study
May/04/2022
Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trial
Oct/06/2021
Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19
Apr/12/2022
Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine
Nov/06/2021
Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study
Sep/24/2020
Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2.
Apr/09/2021
A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomi
Dec/07/2020
Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.
Jun/14/2021
Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns
May/30/2020
Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics
Jul/22/2021
Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019
May/16/2020
Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir
Aug/25/2021
Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial.
Nov/23/2021
Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial
Nov/12/2020
Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2
Sep/13/2020
Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection
Nov/16/2021
A retrospective comparison of drugs against COVID-19
Dec/14/2020
Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations
Jun/01/2020
In silico studies of Potency and safety assessment of selected trial drugs for the treatment of COVID-19.
Jul/22/2021
Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as MPro inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Nov/11/2020
Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters
Dec/09/2021
Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design
Dec/05/2021
Discovery of potent Covid-19 main protease inhibitors using integrated drug-repurposing strategy
Apr/14/2021
Drug repurposing approach to fight COVID-19
Sep/05/2020
Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study.
Oct/01/2020
Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study
Jun/16/2020
A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection
Feb/26/2021
Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study
May/11/2020
Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial
Feb/11/2021
Repurposed Antiviral Drugs for Covid-19 : Interim WHO Solidarity Trial Results
Feb/07/2020
Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy
Nov/11/2021
All-cause mortality among patients treated with repurposed antivirals and antibiotics for COVID-19 in Mexico City: A real-world observational study
Jun/24/2021
Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment
Oct/06/2020
Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
Mar/08/2021
Safety profile of COVID-19 drugs in a real clinical setting
Oct/06/2021
Drug repurposing for SARS-CoV-2: a high-throughput molecular docking, molecular dynamics, machine learning, and DFT study
Apr/27/2022
Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series.
Sep/25/2020
Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production
Sep/21/2020
Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study
Mar/25/2022
Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach.
May/18/2021
A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19
Feb/25/2021
Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study
Jan/11/2022
Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study.
Mar/20/2021
Molecular Docking and Dynamics Simulation Study of Hyrtios erectus Isolated Scalarane Sesterterpenes as Potential SARS-CoV-2 Dual Target Inhibitors.
May/01/2021
Ligand-based quantitative structural assessments of SARS-CoV-2 3CLpro inhibitors: An analysis in light of structure-based multi-molecular modeling evidences
Aug/11/2020
Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: Implication of herb-drug interactions in COVID-19 pharmacotherapy
Jan/19/2021
Potential therapeutic agents against COVID-19: What we know so far
Apr/04/2020
Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface
Jan/25/2021
1,2,4 triazolo[1,5-a] pyrimidin-7-ones as novel SARS-CoV-2 Main protease inhibitors: In silico screening and molecular dynamics simulation of potential COVID-19 drug candidates.
Sep/22/2020
Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease.
Nov/26/2020
Identification of potential inhibitors of SARS-CoV-2 papain-like protease from tropane alkaloids from Schizanthus porrigens: A molecular docking study.
Oct/07/2020
Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19.
Apr/15/2021
Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target
Mar/17/2020
Peptide-like and small-molecule inhibitors against Covid-19
Sep/18/2021
Combination therapy of IFNbeta1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.
Dec/26/2020
In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
Oct/08/2020
Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies
Jan/21/2021
Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study
May/04/2022
The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients
Sep/12/2020
Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients.
Mar/24/2021
Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases
Nov/05/2021
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
May/10/2020
Computational Evaluation of the Inhibition Efficacies of HIV Antivirals on SARS-CoV-2 (COVID-19) Protease and Identification of 3D Pharmacophore and Hit Compounds.
Sep/21/2020
Na+/K+-ATPase as a Target of Cardiac Glycosides for the Treatment of SARS-CoV-2 Infection
Dec/14/2020
[Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality].
Jul/09/2020
SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial.
Aug/03/2020
Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock
May/02/2020
The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial
Dec/30/2020
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Apr/03/2020
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
Apr/28/2020
Plant-derived chemicals as potential inhibitors of SARS-CoV-2 main protease (6LU7), a virtual screening study
Mar/23/2021
Statins and the COVID-19 main protease: in silico evidence on direct interaction
Apr/25/2020
The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19.
May/06/2021
Evaluation of retinotoxicity of COVID-19 treatment: hydroxychloroquine and lopinavir/ritonavir
Sep/28/2020
Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines.
Jan/28/2021
Phytochemicals against SARS-CoV as potential drug leads.
Dec/10/2020
Prophetic Medicine-Nigella Sativa (Black cumin seeds) - Potential herb for COVID-19?
Jul/21/2020
Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients
Apr/17/2020
Destabilizing the structural integrity of COVID-19 by caulerpin and its derivatives along with some antiviral drugs: An in silico approaches for a combination therapy.
Jul/23/2020
Teicoplanin: an alternative drug for the treatment of COVID-19?
Mar/13/2020
Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients
Nov/01/2021
Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection
Jul/16/2020
Topological indices and QSPR/QSAR analysis of some antiviral drugs being investigated for the treatment of COVID-19 patients.
Dec/31/2020
Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection
Jul/31/2020
Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.
Nov/10/2020
Optimal Drug Regimen and Combined Drug Therapy and Its Efficacy in the Treatment of COVID-19: A Within-Host Modeling Study.
May/19/2022
Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations.
Nov/22/2021
Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality
Oct/09/2020
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19.
May/26/2021
Anti-Fungal Drug Anidulafungin Inhibits SARS-CoV-2 Spike-Induced Syncytia Formation by Targeting ACE2-Spike Protein Interaction
Mar/25/2022
Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.
Aug/10/2020
Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study
Jun/23/2021
SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence.
Sep/01/2020
Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series
Jul/23/2020
Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
Oct/13/2020
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Feb/16/2021
Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir
Sep/22/2020
Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics
Jun/14/2020
Efficacy and safety assessment of severe COVID-19 patients with Chinese medicine: A retrospective case series study at early stage of the COVID-19 epidemic in Wuhan, China.
Jan/30/2021
Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels
Apr/30/2022
A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study
Jul/26/2021
Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients
Nov/25/2020
High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment
Apr/13/2020
Tiotropium Is Predicted to Be a Promising Drug for COVID-19 Through Transcriptome-Based Comprehensive Molecular Pathway Analysis
Jul/20/2020
Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression
Mar/12/2020
A triple combination of treatments on moderate COVID-19.
May/14/2021
Antiviral treatment of COVID-19
Jul/12/2021
Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach
Jul/07/2020
Pentoxifylline: A Drug with Antiviral and Anti-Inflammatory Effects to Be Considered in the Treatment of Coronavirus Disease 2019.
Oct/13/2020
Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Aug/23/2021
Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.
Mar/15/2021
Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients
Jan/31/2022
Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.
Dec/18/2020
Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)
Jun/10/2020
Role of favipiravir in the treatment of COVID-19
Oct/30/2020
TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.
Oct/01/2020
Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial
Jul/10/2021
Clinical trials on drug repositioning for COVID-19 treatment
Feb/08/2022
Efficacy of canakinumab in mild or severe COVID-19 pneumonia
Jan/19/2021
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial
Jun/07/2020
A Randomized Clinical Trial of the Efficacy and Safety of Interferon beta-1a in Treatment of Severe COVID-19
Sep/18/2020
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
Aug/10/2021
Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir
Oct/26/2021
Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
Mar/24/2021
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients
Feb/09/2021
Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial
Jun/30/2020
Combination and tricombination therapy to destabilize the structural integrity of COVID-19 by some bioactive compounds with antiviral drugs: insights from molecular docking study.
Jan/08/2021
Insights on 3D Structures of Potential Drug-Targeting Proteins of SARS-CoV-2: Application of Cavity Search and Molecular Docking
Oct/28/2021
Novel cyclohexanone compound as a potential ligand against SARS-CoV-2 main-protease.
Oct/01/2020
Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs
Mar/23/2022
In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel:A Drug Antitarget
May/04/2021
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial.
Jun/29/2021
Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study
Feb/26/2021
Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19
Apr/29/2021
Screening of cryptogamic secondary metabolites as putative inhibitors of SARS-CoV-2 main protease and ribosomal binding domain of spike glycoprotein by molecular docking and molecular dynamics approaches.
Apr/29/2021
Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective obser
Oct/15/2020
Plitidepsin: a Repurposed Drug for the Treatment of COVID-19
Mar/18/2021
In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses
May/29/2020
Dual inhibitors of SARS-CoV-2 proteases: pharmacophore and molecular dynamics based drug repositioning and phytochemical leads
May/30/2020
Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra.
Jan/22/2021
HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect
Apr/04/2022
Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial
Feb/24/2022
Efficiency of antiviral treatment in COVID-19.
Apr/19/2021
Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19
Apr/26/2020
Tocilizumab for treating severe COVID-19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series
Oct/13/2020
Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study
Sep/28/2020
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience
Jan/18/2022
Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review
Feb/22/2021
Exploring existing drugs: proposing potential compounds in the treatment of COVID-19
Feb/25/2021
Candidate drugs against SARS-CoV-2 and COVID-19
Apr/29/2020
Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study
Jun/25/2021
Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
Jul/11/2020
Tocilizumab and liver injury in patients with COVID-19.
Oct/07/2020
Antiviral activities of 4H-chromen-4-one scaffold-containing flavonoids against SARS-CoV-2 using computational and in vitro approaches
Feb/17/2022
Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs
Feb/07/2022
Clinical Trials of Repurposed Antivirals for SARS-CoV-2
Aug/20/2020
Inhibition of drug-metabolizing enzymes by Jingyin granules: implications of herb-drug interactions in antiviral therapy
Jun/28/2021
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing
Jun/16/2020
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study
Jun/19/2020
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
Jan/26/2021
Distance based and bond additive topological indices of certain repurposed antiviral drug compounds tested for treating COVID-19.
Feb/20/2021
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
May/21/2020
Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs
Apr/20/2020
COVID-19 treatment with lopinavir-ritonavir resulting in sick sinus syndrome: a case report.
Jun/30/2020
Versisterol, a new endophytic steroid with 3CL protease inhibitory activity from Avicennia marina (Forssk.) Vierh.
Apr/26/2022
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations
Aug/20/2020
Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China.
Apr/13/2021
Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.
May/11/2021
Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.
Oct/02/2020
Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
Feb/17/2020
Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2
Oct/06/2020
Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
Nov/28/2020
Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification
Oct/31/2020
Blocking the interactions between human ACE2 and coronavirus spike glycoprotein by selected drugs: a computational perspective
Apr/01/2022
Antiviral treatment could not provide clinical benefit in management of mild COVID-19: A Retrospective Experience from Field hospital.
Jul/31/2021
Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus
Jun/09/2020
In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2
Jul/15/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04251871 Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection Recruiting Not Applicable Jan/22/2020 Jan/22/2021
  • Alternative id - 2020001D
  • Interventions - Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 150
  • Age - 14 Years to 80 Years   (Child, Adult, Older Adult)
  • Outcome measures - The incidents of acute respiratory distress syndrome (ARDS) development|The time to fever resolution rate|Time to recovery of lung injury
NCT04350684 Umifenovir in Hospitalized COVID-19 Patients Enrolling by invitation Phase 4 Apr/15/2020 Apr/24/2020
  • Alternative id - Umifenovir in COVID-19
  • Interventions - Drug: Umifenovir|Drug: Interferon-β 1a|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine|Drug: Standards of Care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 40
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events
NCT02735707 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Recruiting Phase 3 Apr/11/2016 Dec/01/2025
  • Alternative id - U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584
  • Interventions - Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Standard course macrolide|Drug: Extended course macrolide|Other: No systemic corticosteroid|Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Fixed-duration higher dose Hydrocortisone|Other: No antiviral agent for influenza|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Other: No antiviral agent for COVID-19|Drug: Lopinavir / Ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Ivermectin|Other: No immune modulation for COVID-19|Drug: Interferon beta-1a|Drug: Anakinra|Drug: Tocilizumab|Drug: Sarilumab|Drug: Local standard venous thromboprophylaxis|Drug: Therapeutic anticoagulation|Drug: Conventional low dose thromboprophylaxis|Drug: Intermediate dose thromboprophylaxis|Drug: Continuation of therapeutic dose anticoagulation|Other: No immunoglobulin|Biological: Convalescent plasma|Biological: Delayed administration of convalescent plasma|Other: No vitamin C|Drug: Vitamin C|Other: No antiplatelet|Drug: Aspirin|Drug: P2Y12 inhibitor|Other: No simvastatin|Drug: Simvastatin|Other: Placebo|Drug: Eritoran|Drug: Apremilast|Procedure: Clinician-preferred mechanical ventilation strategy|Procedure: Protocolised mechanical ventilation strategy|Other: No renin-angiotensin system inhibitor|Drug: Angiotensin converting enzyme inhibitor|Drug: Angiotensin Receptor Blockers|Drug: ARB + DMX-200|Other: No cysteamine|Drug: Cysteamine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Florida, Jacksonville, Florida, United States|Augusta University, Augusta, Georgia, United States|University of Illinois Health, Chicago, Illinois, United States|Tulane Medical Center, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|Brown University - Rhode Island Hospital, Providence, Rhode Island, United States|Canberra Hospital, Canberra, Australian Capital Territory, Australia|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Sutherland Hospital, Caringbah, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|Dubbo Base Hospital, Dubbo, New South Wales, Australia|Northern Beaches Hospital, Frenchs Forest, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|St. George Hospital, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|John Hunter Hospital, Newcastle, New South Wales, Australia|Orange Health Service, Orange, New South Wales, Australia|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|The Prince Charles Hospital, Brisbane, Queensland, Australia|Mater Hospital Brisbane, Brisbane, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Caboolture Hospital, Caboolture, Queensland, Australia|Queen Elizabeth II Jubilee Hospital, Coopers Plains, Queensland, Australia|Logan Hospital, Logan, Queensland, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|Rockhampton Hospital, Rockhampton, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|Townsville Hospital, Townsville, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Lyell McEwin Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Launceston Hospital, Launceston, Tasmania, Australia|Ballarat Base Hospital, Ballarat, Victoria, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|Casey Hospital, Berwick, Victoria, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Dandenong Hospital, Dandenong, Victoria, Australia|Angliss Hospital, Ferntree Gully, Victoria, Australia|Footscray Hospital, Footscray, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Maroondah Hospital, Ringwood East, Victoria, Australia|Sunshine Hospital, Sunshine, Victoria, Australia|Werribee Mercy Hospital, Werribee, Victoria, Australia|St John of God Hospital Midland, Midland, Western Australia, Australia|St John of God Hospital Murdoch, Murdoch, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Subiaco, Subiaco, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Foothills Medical Centre, Calgary, Alberta, Canada|Peter Lougheed Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|South Health Campus, Calgary, Alberta, Canada|Royal Alexandra Hospital, Alberta, Edmonton, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|St Boniface General Hospital, Winnipeg, Manitoba, Canada|Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada|Grace Hospital, Winnipeg, Manitoba, Canada|Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick, Canada|The Moncton Hospital, Fredericton, New Brunswick, Canada|The Saint John General Hospital, Fredericton, New Brunswick, Canada|William Osler Health System, Brampton, Ontario, Canada|Brantford General Hospital, Brantford, Ontario, Canada|Hamilton general Hospital, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St Mary's General Hospital, Kitchener, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Niagara Health, Saint Catharines, Ontario, Canada|Thunder Bay General Hospital, Thunder Bay, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|St Joseph's Health Centre, Toronto, Ontario, Canada|CIUSS Chaudieres-Appalaches (Levis), Lévis, Quebec, Canada|Hospital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Hôpital Fleury, Montréal, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montréal, Quebec, Canada|CHU de Québec - Université Laval, Québec, Quebec, Canada|IUCPQ-UL, Québec, Quebec, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Quebec, Canada|Regina General Hospital, Saskatoon, Saskatchewan, Canada|Universidad de La Sabana, Chía, Cundinamarca, Colombia|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Apollo Main Hospital, Chennai, Tamil Nadu, India|Apollo First Med Hospital, Chennai, Tamil Nadu, India|Apollo Vanagaram Hospital, Chennai, Tamil Nadu, India|Apollo Speciality Hospital - OMR, Chennai, Tamil Nadu, India|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|St. Marianna University Yokohama City Seibu Hospital, Yokohama, Kanagawa, Japan|Saiseikai Kumamoto Hospital, Minami, Kumamoto, Japan|Osaka City General Hospital, Osaka, Japan|Nerima Hikarigaoka Hospital, Tokyo, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Itabashi Chuo Medical Center, Tokyo, Japan|Tokyo bay Urayasu-Ichikawa Medical Center, Tokyo, Japan|Wakayama Medical University, Wakayama, Japan|Chitwan Medical College, Bharatpur, Nepal|Grande International Hospital, Kathmandu, Nepal|Hospital for Advanced Medicine and Surgery (HAMS), Kathmandu, Nepal|Nepal Mediciti, Kathmandu, Nepal|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Taranaki Base Hospital, New Plymouth, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Ziauddin University Hospital Clifton Campus, Karachi, Sindh, Pakistan|Abbasi Shaheed Hospital, Karachi, Sindh, Pakistan|National Institute of Cardiovascular Diseases, Karachi, Karachi, Sindh, Pakistan|South City Hospital, Karachi, Karachi, Sindh, Pakistan|Ziauddin University North Nazimabad Campus, Karachi, Sindh, Pakistan|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes", Bucharest, Romania|King Abdulaziz Medical City, Riyadh, Saudi Arabia|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basildon Hospital, Basildon, England, United Kingdom|Basingstoke and North Hampshire Hospital, Basingstoke, England, United Kingdom|Royal United Hospital, Bath, Bath, England, United Kingdom|Queen Elizabeth Hospital Birmingham, Birmingham, England, United Kingdom|Birmingham City Hospital, Birmingham, England, United Kingdom|Blackburn Hospital, Blackburn, England, United Kingdom|Pilgrim's Hospital, Boston, England, United Kingdom|Royal Bournemouth Hospital, Bournemouth, England, United Kingdom|Royal Sussex County Hospital, Brighton, England, United Kingdom|Southmead Hospital, Bristol, England, United Kingdom|Bristol Royal Hospital, Bristol, England, United Kingdom|Queen's Hospital, Burton, Burton on Trent, England, United Kingdom|Royal Papworth Hospital, Cambridge, England, United Kingdom|Addenbrookes Hospital, Cambridge, England, United Kingdom|Cumberland Royal Infirmary, Carlisle, England, United Kingdom|Ashford & St Peters Hospital Trust, Chertsey, England, United Kingdom|Chesterfield Royal Hospital, Chesterfield, England, United Kingdom|Countess of Chester Hospital, Chester, England, United Kingdom|Colchester Hospital, Colchester, England, United Kingdom|University Hospital Coventry, Coventry, England, United Kingdom|North Manchester General Hospital, Crumpsall, England, United Kingdom|Darlington Memorial Hospital, Darlington, England, United Kingdom|Darent Valley Hospital, Dartford, England, United Kingdom|Russells Hall Hospital, Dudley, England, United Kingdom|University Hospital of North Durham, Durham, England, United Kingdom|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom|Frimley Park Hospital, Frimley, England, United Kingdom|Queen Elizabeth Hospital, Gateshead, England, United Kingdom|Medway Maritime Hospital, Gillingham, England, United Kingdom|James Paget Kings Lynn Hospital, Great Yarmouth, England, United Kingdom|Royal Surrey County Hospital, Guildford, England, United Kingdom|Northwick Park Hospital, Harrow, England, United Kingdom|Hereford County Hospital, Hereford, England, United Kingdom|Barnet Hospital, High Barnet, England, United Kingdom|Huddersfield Hospital, Huddersfield, England, United Kingdom|King George Hospital, Ilford, England, United Kingdom|Ipswich Hospital, Ipswich, England, United Kingdom|Kettering Hospital, Kettering, England, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|Glenfield Hospital, Leicester, England, United Kingdom|Lincoln County Hospital, Lincoln, England, United Kingdom|Liverpool Heart and Chest Hospital, Liverpool, England, United Kingdom|Alder Hey Hospital, Liverpool, England, United Kingdom|Royal Liverpool Hospital, Liverpool, England, United Kingdom|University Hospital Aintree, Liverpool, England, United Kingdom|Croydon University Hospital, London, England, United Kingdom|Royal London Hospital, London, England, United Kingdom|Whipps Cross Hospital, London, England, United Kingdom|Newham Hospital, London, England, United Kingdom|St Barts Hosptial, London, England, United Kingdom|North Middlesex Hospital, London, England, United Kingdom|Royal Free Hospital, London, England, United Kingdom|St Thomas' Hospital, London, England, United Kingdom|Guy's Hospital, London, England, United Kingdom|King's College Hospital, London, England, United Kingdom|St George's Hospital, London, England, United Kingdom|Royal Marsden Hospital, London, England, United Kingdom|Ryal Brompton, London, England, United Kingdom|Hammersmith Hospital, London, England, United Kingdom|St Mary's Hospital, London, England, United Kingdom|Charing Cross Hospital, London, England, United Kingdom|Luton and Dunstable University Hospital, Luton, England, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, England, United Kingdom|Manchester Royal Infirmary, Manchester, England, United Kingdom|The Christie Hospital, Manchester, England, United Kingdom|Wythenshawe Hospital, Manchester, England, United Kingdom|Queen Elizabeth Hospital, Woolwich, Margate, England, United Kingdom|The James Cook University Hospital, Middlesbrough, England, United Kingdom|Milton Keynes University Hospital, Milton Keynes, England, United Kingdom|Royal Victoria Infirmary, Newcastle, Newcastle, England, United Kingdom|Newcastle Freeman Hospital, Newcastle, England, United Kingdom|Northampton General Hospital, Northampton, England, United Kingdom|Norfolk and Norwich University Hospital, Norwich, England, United Kingdom|City Hospital Nottingham, Nottingham, England, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, England, United Kingdom|George Eliot Hospital, Nuneaton, England, United Kingdom|Royal Oldham Hospital, Oldham, England, United Kingdom|Princess Royal University Hospital, Orpington, England, United Kingdom|John Radcliffe Hospital, Oxford, England, United Kingdom|Derriford Hospital, Plymouth, England, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, England, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, England, United Kingdom|Whiston Hospital, Prescot, England, United Kingdom|Royal Preston Hospital, Preston, England, United Kingdom|Royal Berkshire Hospital, Reading, England, United Kingdom|Alexandra Hospital, Redditch, Redditch, England, United Kingdom|Queen's Hospital Romford, Romford, England, United Kingdom|Rotherham General Hospital, Rotherham, England, United Kingdom|Salford Royal Hospital, Salford, England, United Kingdom|Salisbury District Hospital, Salisbury, England, United Kingdom|Royal Hallamshire Hospital, Sheffield, England, United Kingdom|Northern General Hospital, Sheffield, England, United Kingdom|Wexham Park Hospital, Slough, England, United Kingdom|South Tyneside District Hospital, South Shields, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Stepping Hill Hospital, Stockport, England, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, England, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, England, United Kingdom|Sunderland Hospital, Sunderland, England, United Kingdom|King's Mill Hospital, Sutton In Ashfield, England, United Kingdom|Great Western Hospital, Swindon, England, United Kingdom|Western General Hospital, Swindon, England, United Kingdom|Musgrove Park Hospital, Taunton, England, United Kingdom|Torbay and South Devon Hospital, Torquay, England, United Kingdom|Royal Cornwall Hospital, Truro, England, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, England, United Kingdom|Harefield Hospital, Uxbridge, England, United Kingdom|Watford General Hospital, Watford, England, United Kingdom|Southend University Hospital, Westcliff-on-Sea, England, United Kingdom|West Cumberland Hospital, Whitehaven, England, United Kingdom|Royal Albert Edward Infirmary, Wigan, England, United Kingdom|Royal Hampshire Hospital, Winchester, England, United Kingdom|Arrow Park Hospital, Wirral, England, United Kingdom|New Cross Hospital, Wolverhampton, England, United Kingdom|Worcester Royal Hospital, Worcester, England, United Kingdom|York Hospital, York, England, United Kingdom|York Hospital, York, England, United Kingdom|Antrim Area Hospital, Antrim, Northern Ireland, United Kingdom|Royal Victoria Hospital, Belfast, Belfast, Northern Ireland, United Kingdom|Mater Hospital, Belfast, Northern Ireland, United Kingdom|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|Altnagelvin Hospital, Derry, Northern Ireland, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom|Ninewells Hospital, Dundee, Scotland, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom|Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom|Queen Elizabeth University Hospital, Glasgow, Glasgow, Scotland, United Kingdom|Royal Alexandra Hospital, Glasgow, Paisley, Scotland, United Kingdom|Neville Hall Hospital, Abergavenny, Wales, United Kingdom|Glan Clywd Hospital, Bodelwyddan, Wales, United Kingdom|Princess of Wales Hospital, Bridgend, Wales, United Kingdom|University Hospital of Wales, Cardiff, Wales, United Kingdom|Glangwilli Hospital, Carmarthen, Wales, United Kingdom|Grange University Hospital, Cwmbran, Wales, United Kingdom|Royal Gwent Hospital, Newport, Wales, United Kingdom|Royal Glamorgan Hospital, Pontyclun, Wales, United Kingdom|Morriston Hospital, Swansea, Wales, United Kingdom|Wrexham Maelor Hospital, Wrexham, Wales, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 10000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - All-cause mortality|Days alive and not receiving organ support in ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome
NCT04738045 Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients Recruiting Phase 4 Nov/01/2020 Apr/01/2021
  • Alternative id - REC-H-PhBSU-21001
  • Interventions - Drug: Remdesivir|Drug: Lopinavir/ Ritonavir and Remdesivir combination
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Beni-suef University, Banī Suwayf, Egypt
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 90
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Proportion of cured patients in the interventional group versus the proportion of cured patients in the control group|Monitoring of adverse events.
NCT04521400 the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19 Not yet recruiting Phase 2 Aug/20/2020 Sep/11/2020
  • Alternative id - Interferon in COVID
  • Interventions - Drug: High dose Interferon-beta 1a|Drug: Lopinavir/Ritonavir|Drug: Low dose Interferon-beta 1a
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events
NCT04351724 Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) Recruiting Phase 2|Phase 3 Apr/16/2020 Mar/31/2022
  • Alternative id - ACOVACT
  • Interventions - Drug: Chloroquine or Hydroxychloroquine|Drug: Lopinavir/Ritonavir|Other: Best standard of care|Drug: Rivaroxaban|Drug: Thromboprophylaxis|Drug: Candesartan|Drug: non-RAS blocking antihypertensives|Drug: Remdesivir|Drug: Asunercept 400mg|Drug: Asunercept 100mg|Drug: Asunercept 25mg|Drug: Pentaglobin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Medical University of Innsbruck, Innsbruck, Tirol, Austria|Medical University of Graz, Graz, Austria|Kepler University Hospital, Linz, Austria|Medical University of Vienna, Vienna, Austria|Wilhelminenspital, Vienna, Austria|SMZ Süd Kaiser Franz Josef Spital, Vienna, Austria|KH Hietzing, Vienna, Austria|SMZ Baumgartner Höhe Otto Wagner Spital, Vienna, Austria|SMZ Ost Donauspital, Vienna, Austria
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 500
  • Age - 18 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - sustained improvement (>48h) of one point on the WHO Scale|Time to improvement on WHO Scale|Mean change in the ranking on an ordinal scale from baseline|time to discharge or a National Early Warning Score (NEWS) ≤2 (maintained for 24h), whichever occurs first|change from baseline in National Early Warning Score (NEWS)|Oxygenation free days|Incidence of new oxygen use during the trial|duration of oxygen use during the trial|Ventilator free days until day 29|Incidence of new mechanical ventilation use during the trial|duration of mechanical ventilation use during the trial|Viral load/viral clearance|Duration of Hospitalization|Mortality|Obesity - mortality|Obesity - duration of hospitalization|Obesity - ICU admission|Obesity - new oxygen use|Drug-drug interactions with lopinavir/ritonavir|Renin Angiotensin System (RAS) fingerprint|SpO2/FiO2 ratio|paO/FiO2 ratio|modified Sequential Organ Failure Assessment|C-reactive protein|Interleukin-6|procalcitonin|IgM Concentrations|IgA Concentrations|differential blood counts
NCT04376814 Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19 Completed Not Applicable Mar/29/2020 May/25/2020
  • Alternative id - IR.BMSU.REC.1399.017
  • Interventions - Drug: Favipiravir|Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 40
  • Age - 16 Years to 100 Years   (Child, Adult, Older Adult)
  • Outcome measures - Mortality|long of hospitalization|Laboratory Treatment Response (Blood cell count)|Laboratory Treatment Response (CRP )|Dyspnea|Oxygen saturation without supplemental oxygen.|Oxygen therapy
NCT04466241 Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial Recruiting Phase 2|Phase 3 Nov/27/2020 Mar/26/2021
  • Alternative id - ANRS COV01 INTENSE COV
  • Interventions - Drug: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|Drug: Telmisartan 40Mg Oral Tablet|Drug: Atorvastatin 20 Mg Oral Tablet
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Service des Maladies Infectieuses et Tropicales, Centre Hospitalier et Universitaire (CHU) Treichville, Abidjan, Côte D'Ivoire|Centre de Traitement des Maladies Infectieuses (CTMI), CHU de Yopougon, Abidjan, Côte D'Ivoire
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 294
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of patients with undetectable nasopharyngeal swab SARS-CoV-2 PCR and C-reactive protein (CRP) < 27 mg/L at Day 11|Proportion of patients with clinical improvement on the 7-point ordinal scale at Day 11 and Day 28|Kinetics of SARS-CoV-2 viral load|Death rate at Day 11 and Day 28|All causes of death and Acute respiratory distress syndrome (ARDS) at Day 28|Time to hospital discharge|Duration of oxygen supplementation|Prevalence of grade III or IV adverse events|Residual concentration of lopinavir, telmisartan and atorvastatin|Evolution of inflammatory and immunological markers (CRP, fibrinogen, ferritin, d-dimer, dosing of IgG, IgA, IgM; TCD4, CD8, B lymphocytes, NK lymphocytes; naïve/memory T lymphocytes)|Evolution of endothelial activation markers (VEGF and soluble VEGF receptor,VE-cadherin, PECAM/CD31, CD42 and angiopoietin-2)|Proportion of patients with good results according to HIV status|Number of contact cases infected by COVID-19 at Day 28
NCT04365582 OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome Withdrawn Phase 3 May/07/2020 Apr/19/2021
  • Alternative id - OUTCOV
  • Interventions - Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 50 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events
NCT04331470 Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 Recruiting Phase 2|Phase 3 Apr/04/2020 May/20/2020
  • Alternative id - 97548
  • Interventions - Drug: Levamisole Pill + Budesonide+Formoterol inhaler|Drug: Lopinavir/Ritonavir + hydoxychloroquine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 30
  • Age - 15 Years to 100 Years   (Child, Adult, Older Adult)
  • Outcome measures - Clear chest CT-scan|PCR test|Physical statues of patient
NCT04295551 Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe) Unknown status Not Applicable Mar/14/2020 Apr/14/2021
  • Alternative id - QF-XYP1990-1
  • Interventions - Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection|Drug: Lopinavir/ritonavir treatment
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 80
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - Clinical recovery time
NCT04350671 Interferon Beta 1a in Hospitalized COVID-19 Patients Enrolling by invitation Phase 4 Apr/15/2020 Apr/24/2020
  • Alternative id - Interferon Beta 1a in COVID-19
  • Interventions - Drug: Interferon Beta-1A|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 40
  • Age - 50 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events
NCT04779047 Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients. Recruiting Phase 4 Oct/01/2020 Apr/05/2021
  • Alternative id - REC-H-PhBSU-21011
  • Interventions - Drug: Remdesivir|Drug: Hydroxychloroquine|Drug: Tocilizumab|Drug: Lopinavir/ Ritonavir|Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Beni-suef University, Banī Suwayf, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 150
  • Age - 18 Years to 88 Years   (Adult, Older Adult)
  • Outcome measures - Percentage of clinical cure in each arm
NCT04315948 Trial of Treatments for COVID-19 in Hospitalized Adults Recruiting Phase 3 Mar/22/2020 Mar/01/2023
  • Alternative id - C20-15|101015736
  • Interventions - Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care|Drug: AZD7442|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Medizinische Universität Innsbruck, Innsbruck, Austria|Kepler Universitätsklinikum Linz, Linz, Austria|Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität, Salzburg, Austria|Hôpital Erasme - Cliniques universitaires de Bruxelles, Brussels, Belgium|Hôpital Saint Luc, Brussels, Belgium|CHU Brugmann, Brussels, Belgium|Hôpital La Citadelle, Liège, Belgium|Pôle Hospitalier Jolimont / site de Mons-Warquignies, Mons, Belgium|Fakultní nemocnice u sv. Anny v Brně, Brno, Czechia|Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France|Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France|Centre Hospitalier Régional Universitaire de Besançon, Besançon, France|Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France|CHU APHP Ambroise-Paré, Boulogne-Billancourt, France|Centre Hospitalier Andrée Rosemon, Cayenne, France|CHU Clermont-Ferrand, Clermont-Ferrand, France|Hospices Civil, Colmar, France|APHP - hôpital Henri-Mondor, Créteil, France|Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France|Centre Hospitalier Universitaire de Martinique, Fort De France, France|AP-HP Hôpital Bicêtre, Kremlin-Bicêtre, France|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France|Centre hospitalier de Versailles, Le Chesnay, France|Centre Hospitalier Régional Universitaire de Lille, Lille, France|Hospices Civils de Lyon, Lyon, France|Centre Hospitalier de Mont de Marsan, Mont-de-Marsan, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France|Centre Hospitalier Régional et Universitaire de Nancy, Nancy, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalo-Universitaire de Nice, Nice, France|CHU Nîmes, Nîmes, France|APHP - Hôpital Lariboisière, Paris, France|APHP - Hôpital Saint Louis, Paris, France|APHP - Hôpital Saint Antoine, Paris, France|APHP - Hôpital Universitaire Pitié Salpêtrière, Paris, France|APHP - Hôpital Cochin, Paris, France|Hôpital Paris Saint-Joseph et Marie Lannelongue, Paris, France|APHP - Hôpital Necker, Paris, France|APHP- Hôpital Européen Georges-Pompidou, Paris, France|APHP - Hôpital Bichat Claude Bernard, Paris, France|APHP - Hôpital Tenon, Paris, France|CHU Poitiers, Poitiers, France|CH Cornouaille, Quimper, France|CHU de Reims, Reims, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Hopital DELAFONTAINE, Saint-Denis, France|Hôpital d'Instruction des Armées BEGIN, Saint-Mandé, France|Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France|Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier de Tourcoing, Tourcoing, France|Centre Hospitalier Universitaire de Tours, Tours, France|CH Bretagne Atlantique, Vannes, France|CH Bretagne Atlantique, Vannes, France|Centre Hospitalier Annecy Genevois, Épagny, France|Evaggelismos General Hospital, Athens, Greece|General University Hospital of Patras, Patras, Greece|hospital Saint James, Dublin, Ireland|Centre Hospitalier Luxembourg, Luxembourg, Luxembourg|Hôpitaux Robert Schuman, Luxembourg, Luxembourg|Akershus Unniversity Hospital, Oslo, Norway|Lovisenberg Diaconal Hospital, Oslo, Norway|Oslo University Hospital, Oslo, Norway|Bienganski Hospital, Łódź, Poland|Hospital de Abrantes (CHMT), Abrantes, Portugal|Hospital de Cascais, Cascais, Portugal|CHULN- Hospital de Santa Maria, Lisboa, Portugal|CHULN- Hospital de Santa Maria, Lisboa, Portugal|Centro Hospitalar Universitário de São João, EPE, Porto, Portugal|Martin University Hospital, Martin, Slovakia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 2416
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Status on an ordinal scale|National Early Warning Score 2 (NEWS-2 score)|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Need for mechanical ventilation or death by Day 15|Hospitalization|Mortality|Occurrence of new hospitalization|Occurrence of confirmed re-infection with SARS-CoV-2|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 1- 2 hypersensitivity- related and infusion related AEs until D29 visit|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Cumulative incidence of AEs of Special Interest
NCT04409483 Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger Withdrawn Phase 3 Jun/01/2020 Dec/31/2020
  • Alternative id - Trascov
  • Interventions - Drug: Lopinavir-Ritonavir Drug Combination|Combination Product: Standard Care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 12 Years and older   (Child, Adult, Older Adult)
  • Outcome measures - Hospitalization or death|All-cause mortality|Time to hospitalization|Length of hospitalization|Admission to intensive care|Adverse events|Serious adverse events
NCT04328285 Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers Active, not recruiting Phase 3 Apr/14/2020 Mar/30/2022
  • Alternative id - 20PH061|2020-001188-96
  • Interventions - Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r Tablets
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - CHU d'Angers, Angers, France|CHU de Bordeaux, Bordeaux, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|CHU de Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne, Saint-Étienne, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 1200
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)|Evaluation of the occurrence of adverse events in each arm,|Evaluation of the discontinuation rates of the investigational drug in each arm,|Evaluation of the adherence of participants to study drug,|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.|corrected QT interval (ms)
NCT04425382 Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar Recruiting Mar/01/2020 Sep/01/2020
  • Alternative id - MRC-05-069
  • Interventions - Drug: Darunavir/Cobicistat|Drug: Lopinavir/Ritonavir
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Hamad Medical Corporation, Doha, Qatar
  • Study designs - Observational Model: Other|Time Perspective: Retrospective
  • Enrollment - 200
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to Clinical Improvement and/or Virological Clearance (Composite Endpoint)|Percentage of Virological Clearance|Percentage of Clinical Deterioration|Incidence of Adverse Events|Length of Hospital Stay|All-cause Mortality
NCT04276688 Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment Completed Phase 2 Feb/10/2020 Mar/31/2020
  • Alternative id - UW-20-074
  • Interventions - Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 127
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to negative NPS|Time to negative saliva|Time to clinical improvement|Hospitalisation|Mortality|Immune reaction|Adverse events|Time to negative all clinical specimens
NCT04380818 Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 Recruiting Not Applicable Jun/05/2020 Nov/01/2021
  • Alternative id - IPACOVID
  • Interventions - Radiation: Low-dose radiotherapy|Drug: Hydroxychloroquine Sulfate|Drug: Ritonavir/lopinavir|Drug: Tocilizumab Injection [Actemra]|Drug: Azithromycin|Drug: Corticosteroid|Drug: Low molecular weight heparin|Device: Oxygen supply
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care
  • Enrollment - 106
  • Age - 18 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change of the radiological image|Overall mortality|Measure of pro-inflammatory interleukins|Measure of trasforming growth factor (TGF-b)|Measure of tumor necrosis factor alpha (TNF-a)|Determining overexpression of pro-inflammatory selectin|Determining cell adhesion molecules (CAMs)|Measure of marker of oxidative stress PON-1
NCT04275388 Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia Not yet recruiting May/15/2020 Dec/14/2021
  • Alternative id - QF-XYP2001-1
  • Interventions - Drug: Xiyanping injection|Drug: Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride
  • Study type - Observational
  • Study results - No Results Available
  • Locations -
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 426
  • Age - up to 100 Years   (Child, Adult, Older Adult)
  • Outcome measures - Clinical recovery time|Complete fever time|Cough relief time|Virus negative time|Incidence of severe or critical neocoronavirus pneumonia
NCT04381936 Randomised Evaluation of COVID-19 Therapy Recruiting Phase 2|Phase 3 Mar/19/2020 Nov/01/2032
  • Alternative id - NDPHRECOVERY|2020-001113-21|ISRCTN50189673
  • Interventions - Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Biological: Convalescent plasma|Drug: Tocilizumab|Biological: Immunoglobulin|Drug: Synthetic neutralising antibodies|Drug: Aspirin|Drug: Colchicine|Drug: Baricitinib|Drug: Anakinra|Drug: Dimethyl fumarate|Drug: High Dose Corticosteroid|Drug: Empagliflozin|Drug: Sotrovimab
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana|Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India|Eijkman Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology, Jakarta, Indonesia|Clinical Trial Unit, Oxford University Clinical Research Unit-Nepal, Patan Academy of Health Sciences, Kathmandu, Nepal|Wits Health Consortium, Johannesburg, South Africa|RECOVERY Sri Lanka & Pakistan, National Intensive Care Surveillance - M.O.R.U, Colombo, Sri Lanka|Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom|Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 50000
  • Age - Child, Adult, Older Adult
  • Outcome measures - All-cause mortality|Duration of hospital stay|Composite endpoint of death or need for mechanical ventilation or ECMO
NCT04386876 Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions Completed Phase 1 Apr/30/2020 Jun/11/2020
  • Alternative id - NOV2020/01911|FARGE365
  • Interventions - Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet|Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey
  • Study designs - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other
  • Enrollment - 30
  • Age - 20 Years to 40 Years   (Adult)
  • Outcome measures - Primary PK End Points
NCT04261907 Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection Unknown status Not Applicable Feb/07/2020 Jun/30/2020
  • Alternative id - ASC09F-CTP-ZY-01
  • Interventions - Drug: ASC09/ritonavir group|Drug: lopinavir/ritonavir group
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 160
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - The incidence of composite adverse outcome|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requring supplemental oxygen|Rate of undectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Time and rate of laboratory indicators related to disease improvement to return to normal
NCT04455958 Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year Withdrawn Phase 2 May/01/2021 Nov/01/2021
  • Alternative id - STUDY00021444|NCI-2020-02877
  • Interventions - Drug: Lopinavir/Ritonavir|Drug: Placebo Administration|Other: Questionnaire Administration
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Severity of symptoms|Clinical benefit rate of lopinavir/ritonavir|Time to symptom progression|Time to improvement of participants|Time to hospital admission for those who develop severe of critical symptoms|Intensive care unit (ICU) admission: yes or no|Receiving ventilator support: yes or no|Overall survival
NCT04354428 Treatment for COVID-19 in High-Risk Adult Outpatients Active, not recruiting Phase 2|Phase 3 Apr/16/2020 Jan/01/2021
  • Alternative id - STUDY00009878|INV-017062
  • Interventions - Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid|Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 300
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only]|Rate of participant-reported adverse events|COVID-19-related hospitalization days|Rate of disease severity|Viral shedding rates|Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only]
NCT04343768 An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial Completed Phase 2 Apr/09/2020 Apr/27/2020
  • Alternative id - Different Interferons in COVID
  • Interventions - Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Drug: Interferon Beta-1A|Drug: Interferon Beta-1B
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization
NCT04372628 Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 Active, not recruiting Phase 2 Jun/01/2020 Jun/01/2022
  • Alternative id - 200827
  • Interventions - Drug: Lopinavir/Ritonavir 400 mg/100 mg|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Colorado School of Medicine, Aurora, Colorado, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Intermountain, Murray, Utah, United States|University of Wisconsin, Madison, Wisconsin, United States
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 600
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Modified COVID Ordinal Outcomes Scale: Study Day 15|Modified COVID Ordinal Outcome Scale: Study Day 8|Modified COVID Ordinal Outcome Scale: Study Day 29|Proportion of patients hospitalized: Day 1 to 29|Time to hospitalization Day 1 to Day 29|Time to symptom resolution: Day 1 to Day 29|All-cause, all-location mortality: Day 1 to Day 29|Oxygen-free days: Day 1 to Day 29|Fever-free days: Day 1 to Day 29|Ventilator-free days: Day 1 to Day 29|ICU-free days: Day 1 to Day 29|Hospital-free days: Day 1 to Day 29
NCT04364022 Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland Completed Phase 3 Apr/23/2020 Mar/24/2021
  • Alternative id - CCER 2020-00864
  • Interventions - Drug: Lopinavir/ritonavir
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Instituto Nacional de Infectiologia Evandro Chagas, Fiocruz, Rio De Janeiro, Brazil|Universitätsspital Basel and SwissTPH, Basel, Switzerland|Hôpitaux Universitaires de Genève, Geneva, Switzerland|Ospedale Regionale di Lugano, Lugano, Switzerland
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 326
  • Age - 16 Years and older   (Child, Adult, Older Adult)
  • Outcome measures - 21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic at baseline (intent-to-treat (ITT) analysis).|21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)|21-day incidence of SARS-CoV-2 infection in individuals exposed to SARS-CoV-2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)|Severity of clinical COVID-19 on a 7-point ordinal scale
NCT04252885 The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection Completed Phase 4 Jan/28/2020 May/31/2020
  • Alternative id - GZ8H-V1.0 20200122
  • Interventions - Drug: Lopinavir and Ritonavir Tablets|Drug: Arbidol
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 86
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - The rate of virus inhibition|The disease prorogation-temperature|The disease prorogation-respiratory function 1|The disease prorogation-respiratory function 2|The disease prorogation-respiratory function 3
NCT04286503 The Clinical Study of Carrimycin on Treatment Patients With COVID-19 Unknown status Phase 4 Feb/23/2020 Feb/28/2021
  • Alternative id - BeijingYouan Hospital
  • Interventions - Drug: Carrimycin|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|Drug: basic treatment
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 520
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Fever to normal time (day)|Pulmonary inflammation resolution time (HRCT) (day)|Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment
NCT04255017 A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia Unknown status Phase 4 Feb/01/2020 Jul/01/2020
  • Alternative id - TJ20200128
  • Interventions - Drug: Abidol hydrochloride|Drug: Oseltamivir|Drug: Lopinavir/ritonavir
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Department and Institute of Infectious Disease, Wuhan, Hubei, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 400
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery|Rate of undetectable viral RNA
NCT04499677 FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals Completed Phase 2 Sep/24/2020 Dec/01/2021
  • Alternative id - 132084
  • Interventions - Drug: Favipiravir|Drug: Lopinavir/ Ritonavir|Other: Favipiravir Placebo|Other: Lopinavir/ Ritonavir Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Royal Free Hospital, London, United Kingdom|University College London Hospital (UCLH), London, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 240
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Upper respiratory tract viral load at Day 5|Percentage of participants with undetectable upper respiratory tract viral load after 5 days of therapy|Proportion of participants with undetectable stool viral load after 7 days of therapy.|Rate of decrease in upper respiratory tract viral load during 7 days of therapy|Duration of fever following commencement of medication|Proportion of participants with hepatotoxicity after 7 days of therapy|Proportion of participants with other medication-related toxicity after 7 days of therapy and 14 days post-randomisation|Proportion of participants admitted to hospital with COVID-19 related illness|Proportion of participants admitted to ICU with COVID-19 related illness|Proportion of participants who have died with COVID-19 related illness|Pharmacokinetics of favipiravir as measured by Clearance (CL)|Pharmacokinetics of favipiravir as measured by Volume of distribution (V)|Pharmacokinetics of favipiravir as measured by Absorption rate constant (Ka)|Pharmacokinetics of favipiravir as measured by Maximum concentration (Cmax)|Pharmacokinetics of favipiravir as measured by Time to maximum concentration (Tmax)|Pharmacokinetics of favipiravir as measured by Elimination rate constant (Ke)|Pharmacokinetics of favipiravir as measured by Area Under the Curve extrapolated to infinity (AUC (0-inf)|Pharmacodynamics of favipiravir as measured by Rate of viral load decline (delta)|Pharmacodynamics of favipiravir as measured by Maximum increase in viral load under drug treatment (Emax)|Pharmacodynamics of favipiravir as measured by Concentration to achieve half the maximum possible effect (EC50)|Proportion of participants with deleterious or resistance-conferring mutations in SARS-CoV-2 by Day 7 of treatment
NCT04459702 A Study of Combination Therapies to Treat COVID-19 Infection Withdrawn Phase 2 Jul/01/2020 Dec/01/2021
  • Alternative id - PRG-043
  • Interventions - Drug: hydroxychloroquine|Drug: Azithromycin|Drug: Ritonavir|Drug: Lopinavir
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ProgenaBiome, Ventura, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - Efficacy of Treatment by Reduced Symptoms NEWS (National Early Warning System) scores|Efficacy of Treatment by Time to Non-Infectivity|Safety of Dual Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) sores|Safety of Quadruple Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) scores.|Safety of Dual Therapy as Measured by Complete Blood Count|Safety of Quadruple Therapy as Measured by Complete Blood Count|Safety of Dual Therapy as Measured by Metabolic Panel -Albumin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Albumin|Safety of Quadruple Therapy as Measured by Metabolic Panel - A/G Ratio|Safety of Dual Therapy as Measured by Metabolic Panel A/G Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel - Alkaline Phosphatase|Safety of Dual Therapy as Measured by Metabolic Panel Alkaline Phosphatase|Safety of Dual Therapy as Measured by Metabolic Panel - AST|Safety of Quadruple Therapy as Measured by Metabolic Panel - AST|Safety of Quadruple Therapy as Measured by Metabolic Panel - ALT|Safety of Dual Therapy as Measured by Metabolic Panel ALT|Safety of Dual Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel - BUN|Safety of Dual Therapy as Measured by Metabolic Panel - BUN|Safety of Dual Therapy as Measured by Metabolic Panel - Calcium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Calcium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Carbon Dioxide|Safety of Dual Therapy as Measured by Metabolic Panel - Carbon Dioxide|Safety of Dual Therapy as Measured by Metabolic Panel - Chloride|Safety of Quadruple Therapy as Measured by Metabolic Panel - Chloride|Safety of Quadruple Therapy as Measured by Metabolic Panel - Creatinine|Safety of Dual Therapy as Measured by Metabolic Panel - Creatinine|Safety of Dual Therapy as Measured by Metabolic Panel - Globulin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Globulin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Glucose|Safety of Dual Therapy as Measured by Metabolic Panel - Glucose|Safety of Dual Therapy as Measured by Metabolic Panel - Potassium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Potassium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Bilirubin|Safety of Dual Therapy as Measured by Metabolic Panel - Total Bilirubin|Safety of Dual Therapy as Measured by Metabolic Panel - Total Protein|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Protein|Safety of Dual Therapy as Measured by Treatment Related SAE|Safety of Quadruple Therapy as Measured by Treatment Related SAE
NCT04390152 Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19 Recruiting Phase 1|Phase 2 Jan/13/2020 Apr/01/2022
  • Alternative id - BIOXSOMCOV001
  • Interventions - Drug: Wharton's jelly derived Mesenchymal stem cells.|Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - BioXcellerator, Medellin, Antioquia-CO, Colombia|Clinical Somer, Rionegro, Antioquia, Colombia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 40
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Intergroup mortality difference with treatment|Number of patients with treatment related adverse events|Difference in days of mechanical ventilation between groups|Median reduction of days of hospitalization|Median reduction of days of oxygen needs|Difference between "Sequential Organ Failure Assessment" score between groups|Difference between median Murray score between groups|Difference in APACHE II score between groups|Difference in lymphocyte count between groups|Changes in C reactive protein concentration between groups|Changes in D dimer concentration|Changes in ferritin concentration|Changes in lactate dehydrogenase concentration|Impact on interleukin 6 concentrations between groups.|Impact on interleukin 8 concentrations between groups.|Impact on interleukin 10 concentrations between groups.|Impact on tumor necrosis factor alpha concentrations between groups.
NCT04321174 COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir Active, not recruiting Phase 3 Apr/17/2020 Mar/31/2022
  • Alternative id - CORIPREV-1
  • Interventions - Drug: Lopinavir/ritonavir
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - St. Paul's Hospital, Vancouver, British Columbia, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 123
  • Age - 18 Months and older   (Child, Adult, Older Adult)
  • Outcome measures - Microbiologic evidence of infection|Adverse events|Symptomatic COVID-19 disease|Seropositivity|Days of hospitalization attributable to COVID-19 disease|Respiratory failure requiring ventilatory support attributable to COVID-19 disease|Mortality|Short-term psychological impact of exposure to COVID-19 disease|Long-term psychological impact of exposure to COVID-19 disease|Health-related quality of life
NCT05024006 Public Health Emergency: SOLIDARITY TRIAL Philippines Completed Not Applicable Apr/23/2020 Apr/17/2021
  • Alternative id - SJREB-2020-20
  • Interventions - Drug: Remdesivir|Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Drug: Interferon beta-1a|Drug: Acalabrutinib
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Baguio General Hospital, Baguio City, Benguet, Philippines|Cebu Doctor's University Hospital, Cebu City, Cebu, Philippines|Perpetual Succor Hospital Cebu, Cebu City, Cebu, Philippines|Vicente Sotto Memorial Medical Center, Cebu City, Cebu, Philippines|Southern Philippines Medical Center, Davao City, Davao, Philippines|West Visayas University Medical Center, Iloilo City, Iloilo, Philippines|Makati Medical Center, Makati City, Metro Manila, Philippines|Chinese General Hospital, Manila, Metro Manila, Philippines|Manila Doctors Hospital, Manila, Metro Manila, Philippines|ManilaMed - Medical Center Philippines, Manila, Metro Manila, Philippines|San Lazaro Hospital, Manila, Metro Manila, Philippines|UP - Philippine General Hospital, Manila, Metro Manila, Philippines|Asian Hospital and Medical Center, Muntinlupa, Metro Manila, Philippines|Research Institute for Tropical Medicine, Muntinlupa, Metro Manila, Philippines|San Juan de Dios Educational Foundation Inc - Hospital, Pasay, Metro Manila, Philippines|The Medical City, Pasig City, Metro Manila, Philippines|Diliman Doctors Hospital, Quezon City, Metro Manila, Philippines|Fe Del Mundo Medical Center, Quezon City, Metro Manila, Philippines|Lung Center of the Philippines, Quezon City, Metro Manila, Philippines|St Luke's Medical Center Quezon City, Quezon City, Metro Manila, Philippines|University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Metro Manila, Philippines|World Citi Medical Center, Quezon City, Metro Manila, Philippines|Cardinal Santos Medical Center, San Juan, Metro Manila, Philippines|St Luke's Medical Center Global, Taguig, Metro Manila, Philippines|Batangas Medical Center, Batangas, Philippines
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 1314
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - All-cause mortality|Duration of hospital stay|Time to first receiving ventilation
NCT04307693 Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) Terminated Phase 2 Mar/11/2020 Apr/30/2020
  • Alternative id - S2020-0472-0001
  • Interventions - Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 65
  • Age - 16 Years to 99 Years   (Child, Adult, Older Adult)
  • Outcome measures - Viral load|Viral load change|Time to clinical improvement (TTCI)|Percentage of progression to supplemental oxygen requirement by day 7|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7|adverse effects|Concentration of Lopinavir/ritonavir and hydroxychloroquine
NCT04403100 Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1" Recruiting Phase 3 Jun/03/2020 Feb/01/2021
  • Alternative id - COVID19_AMB_Brasil
  • Interventions - Drug: Hydroxychloroquine Sulfate Tablets|Drug: Lopinavir/ Ritonavir Oral Tablet|Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil|Pontificia Universidade Catolica de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Fundo Municipal de Saúde de Betim, Betim, Minas Gerais, Brazil|Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 1968
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of participants who were hospitalized for progression of COVID-19 disease|Proportion of participants who died due to COVID-19 progression and/ or complications|Proportion of participants with viral load change on 03, 07, 10 and 14 after randomization|Time to clinical improvement|Time to clinical failure|Hospitalization for any cause|Proportion of participants who died due to pulmonary complications|Proportion of participants who died due to cardiovascular complications|Proportion of participants who presented with adverse events|Time to improvement on respiratory scale symptoms|proportion of non-adherent participants to any of study drugs
NCT04394182 Ultra Low Doses of Therapy With Radiation Applicated to COVID-19 Recruiting Not Applicable Apr/21/2020 Apr/21/2021
  • Alternative id - 20.4.1597-GHM
  • Interventions - Radiation: Ultra-Low-dose radiotherapy|Device: ventilatory support with oxygen therapy|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Piperacillin/tazobactam|Drug: Low molecular weight heparin|Drug: Corticosteroid injection|Drug: Tocilizumab
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital La Milagrosa, GenesisCare, Madrid, Spain|Hospital Vithas Valencia Consuelo, Valencia, Spain
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care
  • Enrollment - 15
  • Age - 18 Years to 120 Years   (Adult, Older Adult)
  • Outcome measures - Oxygen Therapy Status at Day 2|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 2|Blood Gas Analysis at Day 2|Blood Test at Day 2|Oxygen Therapy Status at Day 5|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 5|Blood Test at Day 5|Oxygen Therapy Status at Day 7|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 7|Blood Test at Day 7|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan at Day 7|Recovery time|COVID-19 status|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan al Month 1|Acute Toxicity
Export (.csv)